AKY-2519

Radiopharmaceutical

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: data expected in 2027 (NCT07581184; Aktis Oncology, Inc., 12 Nov 2026). “AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Metastatic Castration-Resistant Prostate Cancer
NCT07581184 · Aktis Oncology, Inc.
2026-06-17 – 2032-06 · Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
What this study did

Competitive landscape

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AKY-2519: this drugPhase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AKY-2519 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2027-12 · NCT07581184 · CT.gov ↗

Company guidance: data expected in 2027 (Aktis Oncology, Inc., 12 Nov 2026). “AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.” Source ↗

What to watch
2028 (1)
December 2028 (1)
Phase 1Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2028-12 · NCT07887971 · CT.gov ↗
What to watch

See the full readout calendar ↗